QSMetric Potential Indications – Alzheimer’s and related diseases
Discover a potential indication of QSMetric™ technology.
Alzheimer’s disease is a progressive neurodegenerative disorder affecting various brain regions.
The pathophysiological process involves an accumulation of Aβ peptides and Tau proteins associated with intracerebral iron modulation triggering neuronal death via the ferroptosis mechanism.
Alongside Aβ, Tau and phospoTau protein biomarkers, PET-Scan medical imaging enables visualization of Aβ peptide and Tau protein aggregates. Iron accumulations can be visualized and quantified without injection of contrast media using QSM MRI technology.
This is a potential marker of ferroptosis. This quantification of iron by QSM in deep intracerebral regions is potentially linked to prodromal early stages of the disease. QSM could enable earlier detection and improve longitudinal follow-up of patients. This technology is also of great interest for therapeutic follow-up and monitoring the side effects of innovative therapies.
- Caisse nationale de l’Assurance Maladie (CNAM), Data Pathologie, AMELI, Juillet 2024
- Caisse nationale de l’Assurance Maladie (CNAM), Fiche « Démences (dont maladie d’Alzheimer) », Juillet 2024
- Uchida et al, “Quantitative susceptibility mapping as an imaging biomarker for Alzheimer’s disease: The expectations and limitations”, Frontiers in Neuroscience, 2022
- Ravanfar et al, “Systematic Review: Quantitative Susceptibility Mapping (QSM) of Brain Iron Profile in Neurodegenerative Diseases”, Frontiers in Neuroscience, 2021
